Related references
Note: Only part of the references are listed.Pharmacogenetic biomarkers: cytochrome P450 3A5
Iain A. M. MacPhee
CLINICA CHIMICA ACTA (2012)
PPARA: A Novel Genetic Determinant of CYP3A4 In Vitro and In Vivo
Kathrin Klein et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling
Dong Dong et al.
DRUG METABOLISM REVIEWS (2012)
The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients
Laure Elens et al.
PHARMACOGENETICS AND GENOMICS (2012)
Validation of tacrolimus equation to predict troughs using genetic and clinical factors
Chaitali Passey et al.
PHARMACOGENOMICS (2012)
The Role of CYP3A4 mRNA Transcript with Shortened 3′-Untranslated Region in Hepatocyte Differentiation, Liver Development, and Response to Drug Induction
Dan Li et al.
MOLECULAR PHARMACOLOGY (2012)
Dosing equation for tacrolimus using genetic variants and clinical factors
Chaitali Passey et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Genotypes and phenotypes of CYP3A in Bangladeshi population
Abdullah Al Maruf et al.
CLINICA CHIMICA ACTA (2011)
A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients
Laure Elens et al.
CLINICAL CHEMISTRY (2011)
Pharmacogenetics: From Bench to Byte-An Update of Guidelines
J. J. Swen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Analysis of CYP3A4 genetic polymorphisms in Han Chinese
Qing Zhou et al.
JOURNAL OF HUMAN GENETICS (2011)
Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study
Laure Elens et al.
PHARMACOGENETICS AND GENOMICS (2011)
Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients
Laure Elens et al.
PHARMACOGENOMICS (2011)
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
D. Wang et al.
PHARMACOGENOMICS JOURNAL (2011)
Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I
Christine E. Staatz et al.
CLINICAL PHARMACOKINETICS (2010)
Effects of the CYP3A5*3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: a meta-analysis
Hui-Lin Tang et al.
PHARMACOGENETICS AND GENOMICS (2010)
Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects
Yong Zeng et al.
ACTA PHARMACOLOGICA SINICA (2009)
The CYP3A4*18 Genotype in the Cytochrome P450 3A4 Gene, a Rapid Metabolizer of Sex Steroids, Is Associated With Low Bone Mineral Density
Y. S. Kang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference
Pierre Wallemacq et al.
THERAPEUTIC DRUG MONITORING (2009)
The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans
Patrick J. Roberts et al.
DRUG METABOLISM AND DISPOSITION (2008)
Defective Activity of Recombinant Cytochromes P450 3A4.2 and 3A4.16 in Oxidation of Midazolam, Nifedipine, and Testosterone
Mitsue Miyazaki et al.
DRUG METABOLISM AND DISPOSITION (2008)
A comparative study of CYP3A4 Polymorphisms in Mexican Amerindian and Mestizo populations
Octavio D. Reyes-Hernandez et al.
PHARMACOLOGY (2008)
The safety of statins in clinical practice
Jane Armitage
LANCET (2007)
Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5
Nicolas Picard et al.
DRUG METABOLISM AND DISPOSITION (2007)
Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects
Y.-F. Hu et al.
XENOBIOTICA (2007)
Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy
Gerd Schmitz et al.
CURRENT OPINION IN LIPIDOLOGY (2007)
The human cytochrome P450 sub-family: Transcriptional regulation, inter-individual variation and interaction networks
Nick Plant
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2007)
CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates:: Guidelines from an experimental study
V. Haufroid et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
Contemporary management of dyslipidemia in high-risk patients: Targets still not met
Andrew T. Yan et al.
AMERICAN JOURNAL OF MEDICINE (2006)
Factors influencing midazolam hydroxylation activity in human liver microsomes
Ping He et al.
DRUG METABOLISM AND DISPOSITION (2006)
CYP3A phenotypes and genotypes in north Indians
Naushad Rais et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity
A Westlind-Johnsson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Significance of the minor cytochrome P450 3A isoforms
AK Daly
CLINICAL PHARMACOKINETICS (2006)
Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations
MH Davidson et al.
AMERICAN JOURNAL OF CARDIOLOGY (2005)
Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus
LK Kamdem et al.
CLINICAL CHEMISTRY (2005)
Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests
SJ Lee et al.
PHARMACOGENOMICS (2005)
The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?
DA Hesselink et al.
PHARMACOGENOMICS (2005)
Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients
A Wang et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2005)
The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients
V Haufroid et al.
PHARMACOGENETICS (2004)
The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-Å resolution
JK Yano et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Detection of CYP3A4*1B and CYP3A4*2 polymorphisms by RFLP.: Distribution frequencies in a Mexican population
OD Reyes-Hernández et al.
CLINICAL GENETICS (2004)
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
SM Grundy et al.
CIRCULATION (2004)
Evidence of significant contribution from CYP3A5 to hepatic drug metabolism
WL Huang et al.
DRUG METABOLISM AND DISPOSITION (2004)
Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic-polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes
DA Hesselink et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: Studies with sirolimus and midazolam
CL Cummins et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
In vitro metabolism of cyclosporine A by human kidney CYP3A5
Y Dai et al.
BIOCHEMICAL PHARMACOLOGY (2004)
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
DA Hesselink et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes P450: Role of CYP3A4 and CYP3A5
KC Patki et al.
DRUG METABOLISM AND DISPOSITION (2003)
Increased transcriptional activity of the CYP3A4* 1B promoter variant
B Amirimani et al.
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS (2003)
CYP3A4 and MDR1 alleles in a Portuguese population
I Cavaco et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2003)
The cytochrome P450 superfamily: Biochemistry, evolution and drug metabolism in humans
PB Danielson
CURRENT DRUG METABOLISM (2002)
Genetic contribution to variable human CYP3A-mediated metabolism
JK Lamba et al.
ADVANCED DRUG DELIVERY REVIEWS (2002)
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7
JA Williams et al.
DRUG METABOLISM AND DISPOSITION (2002)
Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine
O Burk et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer
AB Spurdle et al.
PHARMACOGENETICS (2002)
CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity
E Garcia-Martin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Identification and functional characterization of eight CYP3A4 protein variants
R Eiselt et al.
PHARMACOGENETICS (2001)
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
P Kuehl et al.
NATURE GENETICS (2001)
CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations
MT Tayeb et al.
PHARMACOGENETICS (2000)
CYP3A activity in African American and European American men:: Population differences and functional effect of the CYP3A4*1B 5′-promoter region polymorphism
C Wandel et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
Evaluation of the genetic component of variability in CYP3A4 activity:: a repeated drug administration method
V Özdemir et al.
PHARMACOGENETICS (2000)
Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes
DS Streetman et al.
PHARMACOGENETICS (2000)
CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity
F Sata et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
Share Paper
